Respiratory syncytial virus (RSV) infection induces significant changes in the pulmonary environment that can unexpectedly impair lung metastatic initiation. Recent research reveals that the host's innate immune response to viral pathogens creates a less permissive landscape for circulating cancer cells. Specifically, this discovery highlights the complex interplay between acute respiratory infections and the early stages of cancer spread.

Mechanism of Lung Metastatic Initiation Inhibition

When a respiratory virus like RSV infects the lungs, it triggers the production of type I interferons (IFNs). These IFNs do not just fight the virus; they also alter the interactions between the lung's structural cells and arriving tumor cells. Consequently, the lung environment becomes hostile to metastatic seeding.

Furthermore, both viral infection and IFN-alpha administration significantly upregulate a protein called Galectin-9. This interferon-inducible protein plays a critical role in restricting the early growth of metastatic nodules. Therefore, the presence of Galectin-9 effectively blocks the ability of cancer cells to colonize the lung tissue. Moreover, this protein acts as a systemic shield against early metastatic expansion.

Clinical Implications for Metastasis Prevention

The study demonstrates that intranasal administration of recombinant IFN-alpha can replicate the anti-metastatic effects of a natural RSV infection. Similarly, this suggests that modulating the lung microenvironment through interferon signaling could become a therapeutic strategy. By inducing Galectin-9 or similar factors, clinicians might one day reduce the risk of secondary tumors in high-risk patients. In addition, these findings provide a better understanding of how common infections shape disease progression.

How does a viral infection prevent cancer spread?

Infections like RSV trigger the release of type I interferons. These proteins change the lung's cellular composition and upregulate protective factors like Galectin-9, making it harder for cancer cells to take root.

Can IFN-alpha be used to treat metastasis?

Experimental models show that intranasal IFN-alpha reduces metastatic seeding. However, further clinical trials are necessary to determine the safety and efficacy of this approach in human cancer patients.

What is the role of Galectin-9?

Galectin-9 is an interferon-inducible protein that directly restricts the ability of cancer cells to seed and grow in the lungs. It acts as a key mediator of the anti-metastatic effect triggered by viral responses.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Farias A et al. Type I interferons induced upon respiratory viral infection impair lung metastatic initiation. Proc Natl Acad Sci U S A. 2026 Apr 21. doi: 10.1073/pnas.2412919123. PMID: 41996163.

Nobumoto A et al. Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology. 2008;18(9):735-44.

Wu L et al. The role of type I interferons in the tumor microenvironment. Cancer Lett. 2023;554:216012.